Tenaya Therapeutics (TNYA) Accumulated Depreciation (2020 - 2026)

Tenaya Therapeutics' Accumulated Depreciation history runs 7 years deep, the most recent figure standing at $41.7 million for Q1 2026.

• In Q1 2026, Accumulated Depreciation rose 19.3% year-over-year to $41.7 million; the TTM figure through Mar 2026 stood at $41.7 million (up 19.3% YoY), while the FY2025 annual figure was $39.9 million, up 23.67% from the prior year.
• Accumulated Depreciation was $41.7 million for Q1 2026 at Tenaya Therapeutics, up from $39.9 million in the prior quarter.
• In the past five years, Accumulated Depreciation ranged from a high of $41.7 million in Q1 2026 to a low of $10.4 million in Q1 2022.
• Historically, Accumulated Depreciation has averaged $26.2 million across 5 years, with a median of $26.5 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Accumulated Depreciation soared 74.09% in 2023, then advanced 19.3% in 2026.
• A 5-year view of Accumulated Depreciation shows it stood at $15.7 million in 2022, then surged by 55.27% to $24.3 million in 2023, then surged by 32.66% to $32.3 million in 2024, then rose by 23.67% to $39.9 million in 2025, then climbed by 4.41% to $41.7 million in 2026.
• The last three Accumulated Depreciation figures came in at $41.7 million (Q1 2026), $39.9 million (Q4 2025), and $38.9 million (Q3 2025), per Business Quant data.